CNBC January 25, 2022
Key Points
– By the time the first Disruptor 50 list was published in 2013, and 23andMe earned a spot on the list, the company had raised more than $50 million from investors.
– As of last September, the company says, nearly 12 million people have had their DNA sequenced by 23andMe, with 80% of them opting in to research that could lead to new drug discoveries.
– It’s thanks in part to 23andMe’s initial disruption that the cost of genomic sequencing has fallen by 99.99% in 16 years, but 23andMe’s future lies in its ability to power the drug discovery that will help it find a way to sustained profitability as the novelty of sequencing one’s own DNA wears...